Application of metabolomics to prostate cancer

Urologic Oncology: Seminars and Original Investigations

Volumn 29, Issue 5, 2011, Pages 572-581

  Trock, Bruce J ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Metabolomics; Personalized medicine; Prostate cancer; Systems biology

Indexed keywords

ALANINE; ASPARAGINE; CHOLESTEROL; CHOLINE; CITRIC ACID; CREATINE; FUMARIC ACID; GLUTAMINE; GLYCEROPHOSPHATE; GLYCEROPHOSPHORYLCHOLINE; GLYCINE METHYLTRANSFERASE; HYDROXYACID; INOSITOL; KYNURENINE; LACTIC ACID; LEUCINE; METHYLTRANSFERASE; PHOSPHOETHANOLAMINE; PHOSPHORYLCHOLINE; POLYAMINE; PROLINE; PROSTATE SPECIFIC ANTIGEN; PYRIMIDINE; PYRUVATE KINASE; SARCOSINE; SPERMINE; TAURINE; THREONINE; URACIL;

BONE METASTASIS; CANCER CELL CULTURE; CANCER DIAGNOSIS; CANCER GROWTH; CANCER STAGING; CARCINOGENESIS; DISEASE ASSOCIATION; DISEASE COURSE; EARLY DIAGNOSIS; ENZYME ACTIVITY; GENE MUTATION; GENETIC REGULATION; GENOMICS; GLEASON SCORE; HUMAN; MASS SPECTROMETRY; METABOLIC PARAMETERS; METABOLITE; METABOLOMICS; PHENOTYPE; PRIORITY JOURNAL; PROSTATE; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATECTOMY; PROTEOMICS; PROTON NUCLEAR MAGNETIC RESONANCE; REVIEW; TISSUE LEVEL; TRANSCRIPTOMICS;

DISEASE PROGRESSION; HUMANS; MALE; METABOLOMICS; PROGNOSIS; PROSTATIC NEOPLASMS;

EID: 80052930281     PISSN: 10781439     EISSN: 18732496     Source Type: Journal    
DOI: 10.1016/j.urolonc.2011.08.002     Document Type: Review

References (46)

1. Cancer Facts and Figures 2011 2011, American Cancer Society, American Cancer Society, Atlanta.
2. Jemal A., Bray F., Center M.M., et al. Global cancer statistics. Ca Cancer J Clin 2011, 61:69-90.
3. Barry M.J. Screening for prostate cancer-the controversy that refuses to die. New Engl J Med 2009, 360:1351-1354.
4. Tosoian J.J., Trock B.J., Landis P., et al. Active surveillance program for prostate cancer: An update of the Johns Hopkins Experience. J Clin Oncol 2011, 29:2185-2190.
5. Eggener S.E., Scardino P.T., Walsh P.C., et al. Predicting 15-year prostate cancer specific mortality after radical prostatectomy. J Urol 2011, 185:869-875.
6. Sreekumar A., Poisson L.M., Rajendiran T.M., et al. Metabolomic profiles delineate potential role for sarcosine in prostate cancer progression. Nature 2009, 457:910-914.
7. Costello L.C., Franklin R.B. Concepts of citrate production and secretion by prostate. 1. Metab Relat Prostate 1991, 18:25-46.
8. Spratlin J.L., Serkova N.J., Eckhardt S.G. Clinical applications of metabolomics in oncology: A review. Clin Cancer Res 2009, 15:431-440.
9. Griffin J.L., Shockcor J.P. Metabolic profiles of cancer cells. Nature Rev Cancer 2004, 4:551-561.
10. Roberts M.J., Schirra H.J., Lavin M.F., et al. Metabolomics: A novel approach to early and noninvasive prostate cancer detection. Korean J Urol 2011, 52:79-89.
11. Taylor J.L., Wu C.L., Cory D., et al. High resolution magic angle spinning proton NMR analysis of human prostate tissue with slow spinning rates. Magn Reson Med 2003, 50:627-632.
12. Xu F., Zou L., Liu Y., et al. Enhancement of the capabilities of liquid chromatography-mass spectrometry with derivatization: General principles and applications. Mass Spectrom Rev 2011 May 9, [Epub ahead of print].
13. DeFeo E.M., Wu C.L., McDougal W.S., et al. A decade in prostate cancer: From NMR to metabolomics. Nat Rev Urol 2011, 8:301-311.
14. Sciarra A., Panebianco V., Salciccia S., et al. Modern role of magnetic resonance and spectroscopy in the imaging of prostate cancer. Urol Oncol 2011, 29:12-20.
15. Koppenol W.H., Bounds P.L., Dang C.V. Otto Warburg's contributions to current concepts of cancer metabolism. Nat Rev Cancer 2011, 11:325-337.
16. Costello L.C., Franklin R.B. The clinical relevance of the metabolism of prostate cancer; zinc, and tumor suppression: Connecting the dots. Mol Cancer 2006, 5:17.
17. Swinnen J.V., Heemers H., Van de Sande T., et al. Androgens, lipogenesis, and prostate cancer. J Steroid Biochem Mol Biol 2004, 92:273-279.
18. Ettinger S.L., Sobel R., Whitmore T.G., et al. Dysregulation of sterolresponse element-binding proteins and downstream effectors in prostate cancer during progression to androgen independence. Cancer Res 2004, 64:2212-2221.
19. Swanson M.G., Vigneron D.B., Tabatabai Z.L., et al. Proton HR-MAS spectroscopy and quantitative pathologic analysis of MRI/3D-MRSI-targeted postsurgical prostate tissues. Magn Reson Med 2003, 50:944-954.
20. Swanson M.G., Keshari K.R., Tabatabai Z.L., et al. Quantification of choline- and ethanolamine-containing metabolites in human prostate tissues using 1H HR-MAS total correlation spectroscopy. Magn Reson Med 2008, 60:33-40.
21. van Asten J.J., Cuijpers V., Hulsbergen-van de Kaa C., et al. High resolution magic angle spinning NMR spectroscopy for metabolic assessment of cancer presence and Gleason score in human prostate needle biopsies. MAGMA 2008, 21:435-442.
22. Serkova N.J., Gamito E.J., Jones R.H., et al. The metabolites citrate, myo-inositol, and spermine are potential age-independent markers of prostate cancer in human expressed prostatic secretions. Prostate 2008, 68:620-628.
23. Kline E.E., Treat E.G., Averna T.A., et al. Citrate concentrations in human seminal fluid and expressed prostatic fluid determined via 1H nuclear magnetic resonance spectroscopy outperform prostate specific antigen in prostate cancer detection. J Urol 2006, 176:2274-2279.
24. Swanson M.G., Zektzer A.S., Tabatabai Z.L., et al. Quantitative analysis of prostate metabolites using 1H HR-MAS spectroscopy. Magn Reson Med 2006, 55:1257-1264.
25. Tessem M.B., Swanson M.G., Keshari K.R., et al. Evaluation of lactate and alanine as metabolic biomarkers of prostate cancer using 1H HR-MAS spectroscopy of biopsy tissues. Magn Reson Med 2008, 60:510-516.
26. Cheng L.L., Burns M.A., Taylor J.L., et al. Metabolic characterization of human prostate cancer with tissue magnetic resonance spectroscopy. Cancer Res 2005, 65:3030-3034.
27. Maxeiner A., Adkins C.B., Zhang Y., et al. Retrospective analysis of prostate cancer recurrence potential with tissue metabolomic profiles. Prostate 2010, 70:710-717.
28. Wagner C., Luka Z. Sarcosine, folate metabolism, and prostate cancer-is there a link?. J Urol 2011, 185:385-386.
29. Song Y.H., Shiota M., Kuroiwa K., et al. The important role of glycine N-methyl transferase in the carcinogenesis and progression of prostate cancer. Mod Pathol 2011 May 13, [Epub ahead of print].
30. Huang Y.C., Lee C.M., Chen M., et al. Haplotypes, loss of heterozygosity, and expression levels of glycine N-methyltransferase in prostate cancer. Clin Cancer Res 2007, 13:1412-1430.
31. Jentzmik F., Stephan C., Miller K., et al. Sarcosine in urine after digital rectal examination fails as a marker in prostate cancer detection and identification of aggressive tumours. Eur Urol 2010, 58:12-18.
32. Sreekumar A., Poisson L.M., Rajendiran T.M., et al. Re: Florian Jentzmik, Carsten Stephan, Kurt Miller, et al. Sarcosine in urine after digital rectal examination fails as a marker in prostate cancer detection and identification of aggressive tumors. Eur Urol 2010, 58:e29-e30. (letter).
33. Colleselli D., Stenzl A., Schwentner C. Re: Florian Jentzmik, Carsten Stephan, Kurt Miller, et al. Sarcosine in urine after digital rectal examination fails as a marker in prostate cancer detection and identification of aggressive tumors. Eur Urol 2010, 58:e51. (letter).
34. Wu H., Liu T., Ma C., et al. GC/MS-based metabolomic approach to validate the role of urinary sarcosine and target biomarkers for human prostate cancer by microwave-assisted derivatization. Anal Bioanal Chem 2011, 401:635-646.
35. Cao D.L., Ye D.W., Zhu Y., et al. Efforts to resolve the contradictions in early diagnosis of prostate cancer: A comparison of different algorithms of sarcosine in urine. Prostate Cancer Prostatic Dis 2011, 14:166-172.
36. Struys E.A., Heijboer A.C., Moorselaar J.V., et al. Serum sarcosine is not a marker for prostate cancer. Ann Clin Biochem 2010, 47:282.
37. Jentzmik F., Stephan C., Lein M., et al. Sarcosine in prostate cancer tissue is not a differential metabolite for prostate cancer aggressiveness and biochemical progression. J Urol 2011, 185:706-711.
38. Thysell E., Surowiec I., Hornberg E., et al. Metabolomic characterization of human prostate cancer bone metastases reveals increased levels of cholesterol. PLoS One 2010, 5:e14175.
39. Schalken J.A. Is urinary sarcosine useful to identify patients with significant prostate cancer?. The trials and tribulations of biomarker development. Eur Urol 2010, 58:19-20.
40. Ransohoff D.F., Gourlay M.L. Sources of bias in specimens for research about molecular markers for cancer. J Clin Oncol 2010, 28:698-704.
41. Lim M.D., Dickherber A., Compton C.C. Before you analyze a human specimen think quality, variability, and bias. Anal Chem 2011, 83:8-13.
42. McShane L.M., Altman D.G., Sauerbrei W., et al. Reporting recommendations for tumor marker prognostic studies (REMARK). J Natl Cancer Inst 2005, 97:1180-1184.
43. Hewavitharana A.K. Re: Florian Jentzmik, Carsten Stephan, Kurt Miller, et al. Sarcosine in urine after digital rectal examination fails as a marker in prostate cancer detection and identification of aggressive tumors. Eur Urol 2010, 58:e39-e40. (letter).
44. Scalbert A., Brennan L., Fiehn O., et al. Mass-spectrometry-based metabolomics: Limitations and recommendations for future progress with particular focus on nutrition research. Metabolomics 2009, 5:435-458.
45. Leek J.T., Scharpf R.B., Bravo H.C., et al. Tackling the widespread and critical impact of batch effects in high-throughput data. Nat Rev Genet 2010, 11:733-739.
46. Mamas M., Dunn W.B., Neyses L., et al. The role of metabolites and metabolomics in clinically applicable biomarkers of disease. Arch Toxicol 2011, 85:5-17.